IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment
- 21 November 2023
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (2) , 148-158
Abstract
Interleukin 35(IL-35) is a newly discovered inhibitory cytokine of the IL12 family. More recently, IL-35 was found to be increased in the tumor microenvironment (TME) and peripheral blood of many patients with cancer, indicating that it plays an important role in the TME. Tumors secrete cytokines that recruit myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg) into the TME to promote malignant progression, which is a great challenge for cancer treatment. Radiotherapy causes serious adverse effects, and tumor resistance to immune checkpoint inhibitors is still an unsolved challenge. Thus, new cancer therapy approaches are urgently needed. Numerous studies have shown that IL-35 can recruit immunosuppressive cells to enable tumor immune escape by promoting the conversion of immune cells into a tumor growth–promoting phenotype as well as facilitating tumor angiogenesis. IL-35-neutralizing antibodies were found to boost the chemotherapeutic effect of gemcitabine and considerably reduce the microvascular density of pancreatic cancer in mice. Therefore, targeting IL-35 in the TME provides a promising cancer treatment target. In addition, IL-35 may be used as an independent prognostic factor for some tumors in the near future. This review intends to reveal the interplay of IL-35 with immune cells in the TME, which may provide new options for the treatment of cancer.Keywords
Funding Information
- Natural Science Foundation of Jiangxi Province (20212ACB216009)
- Natural Science Foundation of Jiangxi Province (20212BAB216048)
- Youth Team Projiect of the Second Affiliated Hospital of Nanchang University (2019YNTD12003)
- Jiangxi Province thousands of Plans (jxsq2019201023)
This publication has 136 references indexed in Scilit:
- Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine familyMolecular Immunology, 2012
- IL-35 Is a Novel Responsive Anti-inflammatory Cytokine — A New System of Categorizing Anti-inflammatory CytokinesPLOS ONE, 2012
- The composition and signaling of the IL-35 receptor are unconventionalNature Immunology, 2012
- Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor Cells in the Tumor Microenvironment via Upregulation of MCP-1PLOS ONE, 2011
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer PatientsJournal of Immunotherapy, 2010
- IL-35-mediated induction of a potent regulatory T cell populationNature Immunology, 2010
- IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10The Journal of Immunology, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- The inhibitory cytokine IL-35 contributes to regulatory T-cell functionNature, 2007